医疗 - 牙科用品

Search documents
Strength Seen in ProDex (PDEX): Can Its 8.2% Jump Turn into More Strength?
ZACKS· 2025-07-29 11:31
Company Overview - Pro-Dex, Inc. (PDEX) shares increased by 8.2% to $53.5 in the last trading session, with a notable trading volume that exceeded the average [1] - The stock has gained 10.1% over the past four weeks, indicating a positive trend [1] Institutional Interest - The recent surge in PDEX shares is attributed to growing institutional interest, with significant investors like Navellier & Associates and Northern Trust either initiating or expanding their positions [2] - This accumulation reflects increasing confidence in the company's fundamentals, supporting the stock's upward momentum that began in August 2024 [2] Earnings Expectations - Pro-Dex is projected to report quarterly earnings of $0.47 per share, representing a year-over-year increase of 2.2% [3] - Expected revenues for the upcoming report are $17.9 million, which is a 19.2% increase compared to the same quarter last year [3] Earnings Estimate Trends - The consensus EPS estimate for Pro-Dex has remained unchanged over the last 30 days, suggesting that the stock's price movement may not sustain without trends in earnings estimate revisions [4] - Monitoring PDEX is advised to determine if the recent price increase can lead to further strength in the future [4] Industry Context - Pro-Dex operates within the Zacks Medical - Dental Supplies industry, where McKesson (MCK) is another key player [5] - McKesson's consensus EPS estimate has changed by 1.1% over the past month to $8.23, reflecting a year-over-year change of 4.4% [6]
Why Is Labcorp (LH) Up 2.5% Since Last Earnings Report?
ZACKS· 2025-05-29 16:37
Core Viewpoint - Labcorp's shares have increased by approximately 2.5% since the last earnings report, which is underperforming compared to the S&P 500 [1] Group 1: Earnings and Estimates - Recent estimates for Labcorp have trended downward over the past month [2] - The magnitude of estimate revisions for Labcorp has been net zero, indicating stability in expectations [4] Group 2: VGM Scores and Rankings - Labcorp has a subpar Growth Score of D and a similar score for momentum, but a B grade for value, placing it in the top 40% for this investment strategy [3] - The overall VGM Score for Labcorp is C, which is relevant for investors not focused on a single strategy [3] - Labcorp holds a Zacks Rank of 3 (Hold), suggesting an expectation of an in-line return in the coming months [4] Group 3: Industry Performance - Labcorp is part of the Zacks Medical - Dental Supplies industry, where West Pharmaceutical Services has seen a slight gain of 0.1% over the past month [5] - West Pharmaceutical reported revenues of $698 million for the last quarter, reflecting a year-over-year increase of 0.4% [5] - The expected earnings for West Pharmaceutical for the current quarter is $1.51 per share, indicating a year-over-year decline of 0.7% [6]